<DOC>
	<DOCNO>NCT02193321</DOCNO>
	<brief_summary>The purpose study evaluate rate new onset postoperative atrial fibrillation subject receive amniotic membrane patch place epicardial surface compare subject undergo epicardium intervention .</brief_summary>
	<brief_title>Safety Efficacy Study Amniotic Membrane Patch Treat Postoperative Atrial Fibrillation</brief_title>
	<detailed_description>New onset postoperative atrial fibrillation ( NOPAF ) present approximately 27 40 % patient recently undergone coronary artery bypass graft ( CABG ) open heart surgery . NOPAF put patient clinical risk stroke arrhythmia . NOPAF commonly prolong hospitalization lead increase use hospital resource , high cost decrease patient satisfaction . A number risk factor associate development NOPAF include age , prior history atrial fibrillation , Chronic Obstructive Pulmonary Disease ( COPD ) , chronic renal failure , diabetes obesity . It entirely clear cause NOPAF ; prevail theory multi-factorial process , possibly due part inflammation surgery . The usual treatment NOPAF associate various side effect risk . We propose test hypothesis amniotic membrane patch , minimal know risk side effect , place heart 's surface surgery reduce incidence NOPAF . This phase I/II prospective , single-center , randomize control clinical trial undertaken ass safety amniotic membrane patch use set CABG surgery whether utilization amniotic membrane patch aid repair normal epicardium follow isolated , first-time CABG procedure might result low rate NOPAF compare subject undergo treatment amniotic membrane patch .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>18 year older This cardiac operation subject 's first primary cardiac operation The subject must undergo isolated CABG procedure use median sternotomy approach Must ability provide write informed consent Must ability fulfill expect requirement clinical protocol Preoperative Prior history atrial fibrillation Prior history open heart surgery Prior history pericarditis Prior history antiarrhythmia drug treatment ( e.g. , amiodarone , dronedarone , sotalol ) past six month The subject implantable cardiac device ( i.e. , cardiac resynchronization therapy device without defibrillator capability ( CRTs CRTDs ) , implantable cardioverterdefibrillators ( ICD ) pacemaker ) Concomitant procedure plan In investigator 's opinion , subject may require prophylactic treatment antiarrhythmia drug temporary pace postoperatively Intraoperative Unexpected procedure ( i.e. , valve repair/replacement ) intraoperative finding create unreasonable intraoperative risk increase probability postoperative complication term recovery . CABG procedure &gt; 3 hour total ( cardiopulmonary bypass ) CPB . Prophylactic use amiodarone . Postoperative Prophylactic use amiodarone No prophylactic , temporary pacing except symptomatic bradycardia advance heart black define : Sinus bradycardia &lt; 40 beat per minute Type 1 atrioventricular ( AV ) block Type 2 AV block Complete block</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Amniotic Membrane</keyword>
</DOC>